TY - JOUR
T1 - Upregulation of myeloperoxidase in patients with opticospinal multiple sclerosis
T2 - Positive correlation with disease severity
AU - Minohara, Motozumi
AU - Matsuoka, Takeshi
AU - Li, Wei
AU - Osoegawa, Manabu
AU - Ishizu, Takaaki
AU - Ohyagi, Yasumasa
AU - Kira, Jun ichi
N1 - Funding Information:
This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan, the Neuroimmunological Disease Research Committee and the Ministry of Health, Labor and Welfare, Japan, for Research on Brain Science. We also thank Ms. Kinukawa (Department of Medical Information Science, Kyushu University Hospital) for help with statistical analyses.
PY - 2006/9
Y1 - 2006/9
N2 - To clarify the role of myeloperoxidase (MPO) in multiple sclerosis (MS), we measured serum MPO levels in 86 Japanese patients with relapsing remitting MS, 47 with opticospinal MS (OSMS) and 39 with conventional MS (CMS), and 85 healthy subjects by sandwich enzyme immunoassays and analyzed relationships with clinical features. We found a significant increase in serum MPO in OSMS patients at relapse and remission, and in CMS patients at remission compared with controls. By logistic regression analysis, the clinical variable associated with high level of MPO at remission in OSMS patients (higher than the mean ± 2 S.D. of healthy controls) was only Kurtzke's Expanded Disability Status Scale (EDSS) score in blood sampling (p = 0.0245); that is, a greater EDSS scores in the high MPO group, whereas in CMS none were associated. The results of our study suggest that MPO levels in remission are related with severe tissue destruction in OSMS.
AB - To clarify the role of myeloperoxidase (MPO) in multiple sclerosis (MS), we measured serum MPO levels in 86 Japanese patients with relapsing remitting MS, 47 with opticospinal MS (OSMS) and 39 with conventional MS (CMS), and 85 healthy subjects by sandwich enzyme immunoassays and analyzed relationships with clinical features. We found a significant increase in serum MPO in OSMS patients at relapse and remission, and in CMS patients at remission compared with controls. By logistic regression analysis, the clinical variable associated with high level of MPO at remission in OSMS patients (higher than the mean ± 2 S.D. of healthy controls) was only Kurtzke's Expanded Disability Status Scale (EDSS) score in blood sampling (p = 0.0245); that is, a greater EDSS scores in the high MPO group, whereas in CMS none were associated. The results of our study suggest that MPO levels in remission are related with severe tissue destruction in OSMS.
UR - http://www.scopus.com/inward/record.url?scp=33748118112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748118112&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2006.05.026
DO - 10.1016/j.jneuroim.2006.05.026
M3 - Article
C2 - 16839613
AN - SCOPUS:33748118112
SN - 0165-5728
VL - 178
SP - 156
EP - 160
JO - Advances in Neuroimmunology
JF - Advances in Neuroimmunology
IS - 1-2
ER -